Skip to main content

Table 2 The characteristics of 3 patient groups, non-ESA, ESA-short, and ESA-long

From: Effect of long-acting erythropoiesis-stimulating agents on hemoglobin levels at the initiation of dialysis

  Non-ESA Short-acting ESA Long-acting ESA p value
Patients number 271 788 204  
Age, years 63.8 ± 14.9 64.2 ± 13.7 67.0 ± 13.9 .021
Male, % 66 65 61 .546
Diabetes, % 47 47 44 .800
BMI, kg/m2 22.3 ± 5.8 23.3 ± 4.5 23.3 ± 4.0 .016
Duration of nephrologist care, days 117 [5, 923] 715 [281, 1723] 872 [307, 1748] .000
Vascular access, % 46 74 86 .000
Diabetic nephropathy 44 45 39 .404
Systolic BP, mmHg 158 ± 25 154 ± 25 154 ± 25 .070
Diastolic BP, mmHg 82 ± 15 78 ± 14 80 ± 15 .000
CTR, % 55 ± 8 53 ± 6 53 ± 6 .002
Hemoglobin, g/dL 8.6 ± 1.6 8.7 ± 1.5 9.5 ± 1.4 .000
Hemoglobin/dose of ESAa - 0.51 [0.36, 0.73] 0.40 [0.28, 0.72] .000
Albumin, g/dL 3.3 ± 0.6 3.4 ± 0.6 3.5 ± 0.5 .002
Creatinine, mg/dL 8.9 ± 3.4 9.6 ± 3.3 9.6 ± 3.1 .012
eGFR, mL/min/1.732 5.7 ± 3.0 5.1 ± 1.9 4.9 ± 2.0 .000
Total cholesterol, mg/dL 186 ± 64 172 ± 47 162 ± 44 .000
Triglyceride, mg/dL 122 [84, 182] 109 [78, 154] 110 [83, 150] .082
HDL-C, mg/dL 50 ± 19 49 ± 17 47 ± 16 .473
Calcium, mg/dL 7.8 ± 1.1 7.9 ± 1.0 8.0 ± 1.0 .013
Phosphate, mg/dL 6.3 ± 1.8 6.0 ± 1.5 6.3 ± 1.6 .010
Ca x P product 47 ± 16 47 ± 12 49 ± 15 .067
i-PTH, pg/mL 291 [171, 421] 265 [168, 403] 291 [168, 446] .176
CRP, mg/dL 0.10 [0.05, 0.17] 0.10 [0.02, 0.13] 0.14 [0.04, 0.20] .000
glucose, mg/dL 132 ± 55 140 ± 52 138 ± 50 .156
Fe, μg/dL 72 ± 36 67 ± 34 65 ± 38 .167
TIBC, μg/dL 231 ± 56 233 ± 45 236 ± 43 .644
Ferritin, ng/dL 140 [73, 282] 117 [57, 204] 105 [49, 193] .077
Dose of ESA, per month 0 12,000 [12,000, 24,000] 24,000 [12,000, 36,000] .000
ARB/ACE-I, % 56 67 65 .003
Vitamin D, % 21 31 44 .000
AST-120, % 9 22 18 .000
Iron, % 10 21 23 .001
  1. Data are expressed as the mean ± SD, median [interquartile range], or percentage
  2. BMI body mass index, BP blood pressure, CTR cardiothoracic ratio, eGFR estimated glomerular filtration rate, HDL-C high density lipoprotein, i-PTH intact parathyroid hormone, CRP c-reactive protein, TIBC total iron-binding capacity, ESA erythropoiesis-stimulating agents, ARB angiotensin receptor blocker, ACE-I angiotensin-converting enzyme inhibitor
  3. aHemoglobin was corrected by dose of ESA per 1000units